Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus

Rheumatology (United Kingdom)

Volumn 53, Issue 2, 2014, Pages 381-382

  Quartuccio, Luca ^a   Rupolo, Maurizio ^b   Michieli, Mariagrazia ^b   De Vita, Salvatore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

AGED; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE THYROIDITIS; CASE REPORT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HERPES SIMPLEX KERATITIS; HUMAN; INFLAMMATION; LETTER; LOW DRUG DOSE; LYMPHOCYTOPENIA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; VEIN THROMBOSIS;

AGED; BORONIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEASOME INHIBITORS; PYRAZINES; TREATMENT OUTCOME;

EID: 84892543108     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket284     Document Type: Letter

References (10)

1. Fröhlich K, Holle JU, Aries PM et al. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011;70:1344-5.
2. Neubert K, Meister S, Moser K et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748-55.
3. Hainz N, Thomas S, Neubert K et al. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol 2012; 120:e47-58.
4. Meister S, Schubert U, Neubert K et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783-92.
5. van der Vlag J, Berden JHM. Proteasome inhibition: a new therapeutic option in lupus nephritis? Nephrol Dial Transplant 2008;23:3771-2.
6. Palumbo A, Bringhen S, Ludwig H et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011;118:4519-29.
7. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
8. Bringhen S, Larocca A, Rossi D et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-53.
9. Tokuhira M, Watanabe R, Nemoto T et al. Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma. Leuk Res 2011;35:591-7.
10. Fukushima T, Nakamura T, Iwao H et al. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res 2011; 31:2297-302.